Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease

Blood

Volumn 123, Issue 2, 2014, Pages 290-299

  Brüggen, Marie Charlotte ^a   Klein, Irene ^a   Greinix, Hildegard ^b   Bauer, Wolfgang ^a   Kuzmina, Zoya ^b   Rabitsch, Werner ^b   Kalhs, Peter ^b   Petzelbauer, Peter ^a   Knobler, Robert ^a   Stingl, Georg ^a   Stary, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CXCL9 CHEMOKINE; CYCLOSPORIN A; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE DERIVED CHEMOKINE; MESSENGER RNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY; REDUCED INTENSITY CONDITIONING; SKIN BIOPSY; SKIN DISEASE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; BIOPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION;

ADULT; BIOPSY; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CYTOKINE; RETROSPECTIVE STUDIES; SKIN DISEASES; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS;

EID: 84897018784     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-514372     Document Type: Article

References (49)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373(9674): 1550-1561.
2. Higman MA, Vogelsang GB Chronic graft versus host disease. Br J Haematol. 2004; 125(4): 435-454. (Pubitemid 38916189)
3. Filipovich AH, Weisdorf D, Pavletic S., et al National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12): 945-956. (Pubitemid 41754712)
4. Wagner JL, Murphy GF Pathology and pathogenesis of cutaneous graft-vs.-host-disease. In: Ferrara JL, Cooke KR, Deeg HJ, eds. Graft-vs-host disease. New York, NY: Marcel Dekker; 2005: 229-255.
5. Lerner KG, Kao GF, Storb R, Buckner C.D., Clift RA, Thomas ED Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974; 6(4): 367-371.
6. Shulman HM, Kleiner D, Lee S.J., et al Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006; 12(1): 31-47. (Pubitemid 43034096)
7. Krenger W, Ferrara JL Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996; 15(1): 50-73. (Pubitemid 26142222)
8. Yi T, Chen Y, Wang L., et al Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009; 114(14): 3101-3112.
9. Nikolic B, Lee S, Bronson R.T., Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000; 105(9): 1289-1298. (Pubitemid 30266082)
10. Burman AC, Banovic T, Kuns R.D., et al IFN-gamma differentially controls the development of idiopathic pneumonia syndrome and graft-versus-host disease of the gastrointestinal tract. Blood. 2007; 110(3): 1064-1072. (Pubitemid 47267449)
11. Yi T, Zhao D, Lin C.L., et al Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008; 112(5): 2101-2110.
12. 1 T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011; 117(12): 3268-3276.
13. Murphy WJ, Welniak LA, Taub D.D., et al Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998; 102(9): 1742-1748. (Pubitemid 28516259)
14. Cheng H, Tian J, Li Z., et al TH17 cells are critical for skin-specific pathological injury in acute graft-versus-host disease. Transplant Proc. 2012; 44(5): 1412-1418.
15. Carlson MJ, West ML, Coghill J.M., Panoskaltsis-Mortari A, Blazar BR, Serody JS In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009; 113(6): 1365-1374.
16. Yeh SP, Liao YM, Lo W.J., et al Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. PLoS ONE. 2012; 7(9):e44416.
17. Dander E, Balduzzi A, Zappa G., et al Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation. 2009; 88(11): 1261-1272.
18. Ratajczak P, Janin A, Peffault de Latour R, et al. Th17/Treg ratio in human graft-versus-host disease. Blood. 2010; 116(7): 1165-1171.
19. Broady R, Yu J, Chow V., et al Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood. 2010; 116(25): 5748-5751.
20. 1 T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation. PLoS ONE. 2012; 7(12):e50896.
21. Liu Y, Cai Y, Dai L., et al The expression of Th17-associated cytokines in human acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013; 19(10): 1421-1429.
22. Malard F, Bossard C, Brissot E., et al Increased plasmacytoid dendritic cells and RORgammat-expressing immune effectors in cutaneous acute graft-versus-host disease [published online ahead of print August 29, 2013]. J Leukoc Biol.
23. Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007; 13(1 Suppl 1): 2-10. (Pubitemid 46044113)
24. Nishimori H, Maeda Y, Teshima T., et al Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood. 2012; 119(1): 285-295.
25. Chen X, Vodanovic-Jankovic S, Johnson B., Keller M, Komorowski R, Drobyski WR Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007; 110(10): 3804-3813. (Pubitemid 350159652)
26. 1 regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005; 106(8): 2903-2911. (Pubitemid 41510772)
27. high regulatory T cells. Blood. 2004; 103(6): 2410-2416. (Pubitemid 38326268)
28. Koreth J, Matsuoka K, Kim H.T., et al Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011; 365(22): 2055-2066.
29. Socié G. Chronic GVHD: B cells come of age. Blood. 2011; 117(7): 2086-2087.
30. Chu YW, Gress RE Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008; 14(4): 365-378.
31. McCormick LL, Zhang Y, Tootell E., Gilliam AC Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999; 163(10): 5693-5699.
32. Castor MG, Pinho V, Teixeira MM The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. Front Pharmacol. 2012; 3: 23.
33. Reshef R, Luger SM, Hexner E.O., et al Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367(2): 135-145.
34. Bangert C, Friedl J, Stary G., Stingl G, Kopp T. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J Invest Dermatol. 2003; 121(6): 1409-1418. (Pubitemid 38005494)
35. Przepiorka D, Weisdorf D, Martin P., et al 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6): 825-828.
36. Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006; 43(2): 75-84. (Pubitemid 44094007)
37. Nograles KE, Zaba LC, Shemer A, et al IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009; 123(6): 1244-1252, e2.
38. Witte E, Witte K, Warszawska K., Sabat R, Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010; 21(5): 365-379.
39. Dhople V, Krukemeyer A, Ramamoorthy A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta. 2006; 1758(9): 1499-1512. (Pubitemid 44444831)
40. Hanash AM, Dudakov JA, Hua G, et al Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012; 37(2): 339-350.
41. Soumelis V, Reche PA, Kanzler H, et al Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7): 673-680. (Pubitemid 34752477)
42. He R, Geha RS Thymic stromal lymphopoietin. Ann N Y Acad Sci. 2010; 1183: 13-24.
43. Bogiatzi SI, Fernandez I, Bichet J.C., et al Cutting edge: proinflammatory and Th2 cytokines synergize to induce stromal lymphopoietinproduction by human skin keratinocytes. J Immunol. 2007; 178(6): 3373-3377. (Pubitemid 46417601)
44. Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010; 28(1): 100-108.
45. Schroder K, Hertzog PJ, Ravasi T, Hume DA Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75(2): 163-189. (Pubitemid 38174573)
46. Wenzel J, Tüting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J Invest Dermatol. 2008; 128(10): 2392-2402.
47. Wenzel J, Lucas S, Zahn S., et al CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. J Am Acad Dermatol. 2008; 58(3): 437-442. (Pubitemid 351226304)
48. 1 cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood. 2009; 113(15): 3620-3630.
49. 1 T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012; 120(20): 4246-4255.